Clinical trial

Apalutamide Plus Intermittent Hormone Therapy Versus Intermittent Hormone Therapy Alone in Prostate Cancer

NCT02811809

StatusWITHDRAWN

Study typeINTERVENTIONAL

Start date2020-12-01

PhasePHASE2

Study timeline

Study start (estimated)2020-12-01Date precision: month

Registry last updated2020-02-27

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Prostate Cancerunresolved

Interventions

ApalutamideDRUG · verified · RxNorm: apalutamide

IHTDRUG

Sponsors & collaborators

The University of Texas Health Science Center, Houstonlead sponsor

Janssen Scientific Affairs, LLCcollaborator

Mapped research locations

HoustonTexas, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02811809 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.